Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARL R GRAY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1598873382
CMS profile
949771
Location
OGDEN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,553.20

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,544.11 140
Education $9.09 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARL R GRAY

NPI 1598873382 · CMS profile ID 949771

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OGDEN, UT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598873382?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARL R GRAY, NPI 1598873382, CMS profile ID 949771. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598873382?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CARL R GRAY, NPI 1598873382, CMS profile ID 949771. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598873382?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CARL R GRAY, NPI 1598873382, CMS profile ID 949771, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598873382?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $2,553.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $9.0904/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492429 CMS
E.R. Squibb & Sons, L.L.C. $13.7303/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492431 CMS
Blueprint Medicines Corporation $24.3503/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958938799 CMS
Lilly USA, LLC $19.5403/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917928075 CMS
TerSera Therapeutics LLC $18.3703/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943238319 CMS
Lilly USA, LLC $16.3003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917927089 CMS
Genentech USA, Inc. $24.8303/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950779599 CMS
Janssen Biotech, Inc. $19.8403/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886679787 CMS
Pharmacyclics LLC, an AbbVie Company $24.3103/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890340651 CMS
Celgene Corporation $16.9103/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492423 CMS
GENZYME CORPORATION $14.8603/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938860009 CMS
EMD Serono, Inc. $19.8903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941498669 CMS
GlaxoSmithKline, LLC. $17.6203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944804331 CMS
E.R. Squibb & Sons, L.L.C. $13.1403/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492409 CMS
Myovant Sciences Inc. $14.5803/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941205769 CMS
PFIZER INC. $14.0902/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949073463 CMS
Genentech USA, Inc. $17.9602/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950790441 CMS
EMD Serono, Inc. $13.2702/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941492867 CMS
Astellas Pharma US Inc $16.9002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940124185 CMS
Seagen Inc. $18.0502/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904127957 CMS
EISAI INC. $17.5502/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908024265 CMS
Eisai Inc. $18.6202/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 935311699 CMS
Incyte Corporation $15.1002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943017979 CMS
E.R. Squibb & Sons, L.L.C. $16.8102/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492709 CMS
Daiichi Sankyo Inc. $20.1502/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930803745 CMS
Sobi, Inc $25.3602/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940364359 CMS
AstraZeneca Pharmaceuticals LP $19.7402/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920261231 CMS
AstraZeneca Pharmaceuticals LP $18.0401/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920252215 CMS
GlaxoSmithKline, LLC. $17.5601/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944804333 CMS
Incyte Corporation $12.3801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943017977 CMS
Merck Sharp & Dohme LLC $20.1701/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944080237 CMS
GENZYME CORPORATION $19.5301/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938860001 CMS
Genentech USA, Inc. $19.5001/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950803781 CMS
Genentech USA, Inc. $0.3501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950803783 CMS
EMD Serono, Inc. $15.6801/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941485611 CMS
E.R. Squibb & Sons, L.L.C. $14.8401/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932492407 CMS
Lilly USA, LLC $14.4101/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917931215 CMS
Janssen Biotech, Inc. $16.4001/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886679781 CMS
Seagen Inc. $13.6501/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904127941 CMS
Genentech USA, Inc. $23.9001/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950800253 CMS
Pharmacyclics LLC, an AbbVie Company $22.7801/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890340649 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,529.77 174
PY2020 $1,595.82 97
PY2021 $1,982.96 103
PY2022 $2,553.20 141
PY2023 $4,350.06 160
PY2024 $3,022.46 154
PY2025 $3,159.46 151

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $716.53 1
PY2025 Principal investigator $607,409.33 67
PY2024 Recipient $2,990.13 14
PY2024 Principal investigator $657,485.79 74
PY2023 Principal investigator $471,654.43 47
PY2022 Principal investigator $162,386.93 28
PY2021 Principal investigator $187,277.59 66
PY2020 Principal investigator $115,914.46 45
PY2019 Principal investigator $295,261.79 51

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,657.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415375
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184279024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184279026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184279028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184279030
Principal investigator 1 Janssen Research & Development, LLC $1,488.00 12/15/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415425
Principal investigator 1 ABBVIE INC. $2,091.70 12/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202526468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184269197
Principal investigator 1 Boehringer Ingelheim International GmbH $67.88 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696153
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696155
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696157
Principal investigator 1 Boehringer Ingelheim International GmbH $1,227.60 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696159
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696161
Principal investigator 1 Boehringer Ingelheim International GmbH $285.60 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696163
Principal investigator 1 Boehringer Ingelheim International GmbH $31.62 11/19/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696165
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,500.00 11/19/2025 Non-covered Recipient Entity
Community Cancer Trials Of Utah
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220799147
Principal investigator 1 Amgen Inc. $420.57 11/10/2025 Non-covered Recipient Entity
UT HEMA OCONCOMM
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer No dispute reported 06/30/2026 1246651054
Principal investigator 1 Incyte Corporation $266.40 11/10/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240519678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $244.49 10/23/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184252620
Recipient Eli Lilly and Company $716.53 10/20/2025 Covered Recipient Physician A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LY3537021 FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN ADULT PARTICIPANTS WITH MALIGNANT DISEASE No dispute reported 06/30/2026 1187871121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,066.04 10/16/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184250599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,097.35 10/09/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184248958
Principal investigator 1 SANOFI US SERVICES INC. $11,250.00 10/09/2025 Non-covered Recipient Entity
Community Cancer Trials Of Utah, Llc
Evaluate the efficacy and safety of oral rilzabrutinib as frontline treatment in adults diagnosed with primary ITP No dispute reported 06/30/2026 1226131684
Principal investigator 1 Janssen Research & Development, LLC $6,249.00 10/06/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415431
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 10/01/2025 Non-covered Recipient Entity
Utah Hematology Oncology Ogden Clinic
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations No dispute reported 06/30/2026 1220696151
Principal investigator 1 ABBVIE INC. $14,500.00 09/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202509992
Principal investigator 1 Janssen Research & Development, LLC $1,358.00 09/01/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,809.30 08/21/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184229743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,496.70 08/21/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184229745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $265.74 08/07/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184226137
Principal investigator 1 Janssen Research & Development, LLC $4,720.00 08/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 07/31/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184222834
Principal investigator 1 Janssen Research & Development, LLC $5,095.00 07/25/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415334
Principal investigator 1 Janssen Research & Development, LLC $20,975.00 07/25/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415366
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/25/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $265.74 07/17/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184217068
Principal investigator 1 GlaxoSmithKline, LLC. $10,356.46 07/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192112280
Principal investigator 1 Janssen Research & Development, LLC $40,903.00 07/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,974.40 07/04/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184212867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,482.90 06/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184209183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $265.74 06/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184209185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $265.74 06/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184209187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184209189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,984.78 06/19/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PARTICIPANTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (OLYMPIA-3) No dispute reported 06/30/2026 1184209191
Principal investigator 1 Incyte Corporation $1,000.00 06/03/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240519672
Principal investigator 1 Janssen Research & Development, LLC $2,846.00 05/26/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415411
Principal investigator 1 ABBVIE INC. $3,500.00 05/15/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202484999
Principal investigator 1 Janssen Research & Development, LLC $8,819.00 05/05/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415386
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,613.10 04/30/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185540331
Principal investigator 1 GlaxoSmithKline, LLC. $1,260.00 04/22/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA No dispute reported 06/30/2026 1192112288
Principal investigator 1 Incyte Corporation $1,274.33 04/15/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240519669
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 04/07/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415380
Principal investigator 1 Janssen Research & Development, LLC $3,281.00 04/07/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415416
Principal investigator 1 Janssen Research & Development, LLC $5,420.00 03/31/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415441
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 03/14/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415404
Principal investigator 1 Janssen Research & Development, LLC $17,772.00 03/10/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415360
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,614.20 03/10/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH, LLC
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) No dispute reported 06/30/2026 1190309590
Principal investigator 1 ABBVIE INC. $2,025.00 03/05/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202455862
Principal investigator 1 Amgen Inc. $115,906.22 02/22/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer No dispute reported 06/30/2026 1246640465
Principal investigator 1 AstraZeneca UK Limited $152,771.40 02/12/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH, LLC
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185540335
Principal investigator 1 Janssen Research & Development, LLC $4,195.00 02/10/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415356
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 02/10/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415392
Principal investigator 1 ABBVIE INC. $14,500.00 02/06/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202448129
Principal investigator 1 Janssen Research & Development, LLC $2,716.00 02/03/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH LLC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175415343
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,004.60 01/24/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH, LLC
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185540333
Principal investigator 1 Incyte Corporation $57,893.76 01/14/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240519665
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,393.41 01/01/2025 Non-covered Recipient Entity
COMMUNITY CANCER TRIALS OF UTAH, LLC
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190309588